Document Detail


New oral anticoagulants after acute coronary syndrome.
MedLine Citation:
PMID:  23953902     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
New oral anticoagulants (NOACs) have been developed that may further decrease the mortality and morbidity of ACS by complementing antiplatelet therapy. Optimal use of these agents can be achieved by maximum reduction in thrombotic events at the minimum bleeding risk when combining a long-term oral anticoagulant with anti-platelet therapy in patients with coronary heart disease. Although, based on the pharmacokinetics and -dynamics of NOACs, these agents could improve the current management of ACS patients, multiple trials consistently demonstrate a trend toward increased major and clinically relevant non major bleeding almost diminishing the benefits in reduction of ischemic events. Therefore, some critical issues need to be further evaluated in future trials.
Authors:
N Bennaghmouch; J M Ten Berg
Publication Detail:
Type:  Journal Article     Date:  2013-07-22
Journal Detail:
Title:  Best practice & research. Clinical haematology     Volume:  26     ISSN:  1532-1924     ISO Abbreviation:  Best Pract Res Clin Haematol     Publication Date:  2013 Jun 
Date Detail:
Created Date:  2013-08-19     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101120659     Medline TA:  Best Pract Res Clin Haematol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  141-50     Citation Subset:  IM    
Copyright Information:
© 2013 Elsevier Ltd. All rights reserved.
Affiliation:
Department of Cardiology, St Antonius Hospital Nieuwegein, Koekoekslaan 1, 3435 CM Nieuwegein, The Netherlands. Electronic address: n.bennaghmouch@antoniusziekenhuis.nl.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Novel oral anticoagulants in secondary prevention of stroke.
Next Document:  New oral anticoagulants for the treatment of venous thromboembolism.